Aligos Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 10, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 10, 2025
ALGS$3.95-2.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
Balance Sheets
| December 31,2024 | December 31,2023 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $36,997 | $135,704 |
| Restricted cash | 110 | 70 |
| Short-term investments | 19,942 | - |
| Other current assets | 5,092 | 5,310 |
| Total current assets | 62,141 | 141,084 |
| Operating lease right-of-use assets | 4,964 | 6,559 |
| Property and equipment, net | 2,362 | 3,259 |
| Other assets | 627 | 625 |
| Total assets | $70,094 | $151,527 |
| LIABILITIES AND | ||
| STOCKHOLDERS’ (DEFICIT) EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $2,571 | $2,517 |
| Accrued liabilities | 15,557 | 16,842 |
| Operating lease liabilities, current | 3,422 | 3,229 |
| Finance lease liabilities, current | 36 | 10 |
| Deferred revenue, current | 151 | 1,308 |
| Total current liabilities | 21,737 | 23,906 |
| Operating lease liabilities, net of current portion | 4,795 | 7,668 |
| Finance lease liabilities, net of current portion | 122 | 231 |
| Common warrant liability | 72,367 | 27,596 |
| Long term liability | 46 | 46 |
| Total liabilities | 99,067 | 59,447 |
| Commitments and contingencies (Note 14) | ||
| Stockholders’ (deficit) equity: | ||
| Preferred Stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2024 and December 31, 2023, respectively; no shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively. | - | - |
| Common stock, $0.0001 par value; 20,800,000 shares and 12,800,000 shares authorized as of December 31, 2024 and December 31, 2023, respectively; 3,864,436 and 3,003,855 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively. | 8 | 7 |
| Additional paid-in capital | 588,576 | 578,325 |
| Accumulated deficit | (618,008) | (486,797) |
| Accumulated other comprehensive income | 451 | 545 |
| Total stockholders’ (deficit) equity | (28,973) | 92,080 |
| Total liabilities and stockholders’ (deficit) equity | $70,094 | $151,527 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.